Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay

Therapeutic drug monitoring (TDM) of tumor necrosis factor-α (TNFα)-inhibitors adalimumab and infliximab is important to establish optimal drug dose and maximize treatment efficacy. Currently, TDM is primarily performed with ELISA techniques in clinical laboratories, resulting in a long sample-to-re...

Descripción completa

Detalles Bibliográficos
Autores principales: van Aalen, Eva A., de Vries, Ivar R., Hanckmann, Eva T. L., Stevens, Jeannot R. F., Romagnoli, Thomas R., Derijks, Luc J. J., Broeren, Maarten A. C., Merkx, Maarten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2023
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633107/
https://www.ncbi.nlm.nih.gov/pubmed/38013761
http://dx.doi.org/10.1039/d3sd00131h

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633107/
https://www.ncbi.nlm.nih.gov/pubmed/38013761
http://dx.doi.org/10.1039/d3sd00131h

Ejemplares similares